ID   A2780ADR
AC   CVCL_1941
SY   A2780-ADR; A2780 ADR
DR   CLO; CLO_0001572
DR   BioGRID_ORCS_Cell_line; 826
DR   cancercelllines; CVCL_1941
DR   CancerTools; 152707
DR   Cell_Model_Passport; SIDM01211
DR   ChEMBL-Cells; CHEMBL3988401
DR   Cosmic; 1139224
DR   ECACC; 93112520
DR   GEO; GSM827329
DR   GEO; GSM1291127
DR   LINCS_LDP; LCL-1694
DR   Progenetix; CVCL_1941
DR   PubChem_Cell_line; CVCL_1941
DR   Wikidata; Q54606613
DR   Ximbio; 152707
RX   PubMed=11416159;
RX   PubMed=20215515;
RX   PubMed=25230021;
RX   PubMed=30971826;
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (PubMed=25230021).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): ECACC; PubMed=11416159; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 11,14
ST   D18S51: 15
ST   D19S433: 12
ST   D21S11: 28
ST   D2S1338: 21,22
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 14,15,16,17 (PubMed=25230021)
ST   D8S1179: 15,16,17 (PubMed=11416159)
ST   FGA: 19,25
ST   Penta D: 8,9
ST   Penta E: 10,13
ST   TH01: 6 (ECACC; PubMed=25230021)
ST   TH01: 6,9.3 (PubMed=11416159)
ST   TPOX: 8,9
ST   vWA: 15,16
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 25
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//